07:35 AM EDT, 08/08/2025 (MT Newswires) -- Akero Therapeutics ( AKRO ) reported a Q2 net loss Friday of $0.86 per diluted share, wider than a loss of $0.81 a year earlier.

An analyst polled by FactSet expected a loss of $0.96.

The company did not report any revenue for the quarter ended June 30.

As of June 30, the company said it had $1.09 billion in cash, cash equivalents, and short-and long-term marketable securities, expected to finance operations through 2028.